Therapy for hepatic fibrosis: Revisiting the preclinical models

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 8-9, 2011, Pages 521-525

  Bissell, D Montgomery ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CARBON TETRACHLORIDE; GAMMA1B INTERFERON; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

DRUG TREATMENT FAILURE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; LIVER FIBROSIS; LIVER FUNCTION; LUNG FUNCTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; STELLATE CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS;

EID: 80052548485     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.03.009     Document Type: Short Survey

References (32)

1. Friedman S.L., Rockey D.C., Bissell D.M. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 2007, 45:242-249.
2. Friedman S.L., Roll F.J., Boyles J., Bissell D.M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985, 82:8681-8685.
3. Knook D.L., Seffelaar A.M., de Leeuw A.M. Fat-storing cells of the rat liver. Their isolation and purification. Exp Cell Res 1982, 139:468-471.
4. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008, 12:939-962. [xi].
5. Schuppan D., Popov Y. Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 2009, 33:949-957.
6. Czaja M.J., Weiner F.R., Takahashi S., Giambrone M.A., van der Meide P.H., Schellekens H., et al. Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1989, 10:795-800.
7. Rockey D.C., Maher J.J., Jarnagin W.R., Gabbiani G., Friedman S.L. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992, 16:776-784.
8. Ziesche R., Hofbauer E., Wittmann K., Petkov V., Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
9. Granstein R.D., Rook A., Flotte T.J., Haas A., Gallo R.L., Jaffe H.S., et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol 1990, 126:1295-1302.
10. Pockros P.J., Jeffers L., Afdhal N., Goodman Z.D., Nelson D., Gish R.G., et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007, 45:569-578.
11. King T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374:222-228.
12. du Bois R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9:129-140.
13. Pond S.M. Effects on the liver of chemicals encountered in the workplace. West J Med 1982, 137:506-514.
14. Shi Z., Wakil A.E., Rockey D.C., Rockey D.C., Maher J.J., Jarnagin W.R., et al. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Proc Natl Acad Sci U S A 1997, 94:10663-10668.
15. Bissell D.M. Inflammation and hepatic fibrosis. Semin Liver Dis 2010, 30:211-214.
16. Berres M.L., Koenen R.R., Rueland A., Zaldivar M.M., Heinrichs D., Sahin H., et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010, 120:4129-4140.
17. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
18. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S.L., Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660-670.
19. Wang B., Dolinski B.M., Kikuchi N., Leone D.R., Peters M.G., Weinreb P.H., et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 2007, 46:1404-1412.
20. Rosmorduc O., Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010, 30:258-270.
21. Bissell D.M., Roulot D., George J. Transforming growth factor beta and the liver. Hepatology 2001, 34:859-867.
22. Gressner A.M., Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006, 10:76-99.
23. Sanford L.P., Ormsby I., Gittenberger-de Groot A.C., Sariola H., Friedman R., Boivin G.P., et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124:2659-2670.
24. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
25. Cheng N., Bhowmick N.A., Chytil A., Gorksa A.E., Brown K.A., Muraoka R., et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-MSP- and HGF-mediated signaling networks. Oncogene 2005, 24:5053-5068.
26. Xu Y., Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 2007, 16(Spec No. 1):R14-R20.
27. Rachmawati H., Reker-Smit C., Lub-de Hooge M.N., van Loenen-Weemaes A., Poelstra K., Beljaars L. Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine. Drug Metab Dispos 2007, 35:814-821.
28. George J., Roulot D., Koteliansky V.E., Bissell D.M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719-12724.
29. Qi Z., Atsuchi N., Ooshima A., Takeshita A., Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 1999, 96:2345-2349.
30. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328.
31. Beaussier M., Wendum D., Fouassier L., Rey C., Barbu V., Lasnier E., et al. Adaptative bile duct proliferative response in experimental bile duct ischemia. J Hepatol 2005, 42:257-265.
32. Wynn T.A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010, 30:245-257.